Rexahn Pharmaceuticals (RNN) 0.75 $RNN
Hot Stock: Rexahn Pharmaceuticals, Shares Gain 6.5% (RNN)
Comtex SmarTrend(R) - Fri Mar 20, 10:17AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 6.5% to $0.75 on 1.4x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 800,000 shares, vs. average volume of 567,000 shares per day. The stock has outperformed the Dow (6.5% to the Dow's 1.0%) and outperformed the S&P 500 (6.5% to the S&P's 0.8%) during today's trading.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference in Tokyo, Japan
GlobeNewswire - Wed Mar 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director of Business Development, will present at the 12 Annual BIO Asia International Conference in Tokyo, Japan on Wednesday, March 25, 2015 at 11:15 AM. (Japan Time). The conference is being held on March 24 to 25, 2015 at the Grand Hyatt, Tokyo, Japan.
RNN: 0.75 (+0.05)
Rexahn Pharma FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 8:33AM CDT
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals reports FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 8:12AM CDT
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update
GlobeNewswire - Tue Mar 17, 8:00AM CDT
-- Supinoxin(TM) and RX-3117 Phase I clinical trials expected to be completed in the first half of 2015
RNN: 0.75 (+0.05)
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 11.76 (-0.32), RNN: 0.75 (+0.05), PTBI: 2.91 (-0.40), DARA: 0.82 (unch), BIND: 5.87 (-0.01)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.75 (+0.05), NBIX: 43.60 (-0.65), ITEK: 5.75 (-0.19), ARIA: 8.69 (-0.28), ARRY: 8.00 (-0.09)
Rexahn Pharmaceuticals to Present at the ROTH Capital Partners 27th Annual Growth Stock Conference
GlobeNewswire - Mon Mar 02, 8:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer will present at the ROTH Capital Partners 27 Annual Growth Stock Conference on Monday, March 9, 2015 at 1:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals to Present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
GlobeNewswire - Wed Feb 18, 8:09AM CST
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director of Business Development, will present at the 3 Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Monday, February 23, 2015 at 9:15 a.m. Eastern Standard Time. The conference takes place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
RNN: 0.75 (+0.05)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 4.15 (+0.12), INSM: 21.80 (-0.20), RNN: 0.75 (+0.05), ZSPH: 49.38 (-2.11), RDHL: 13.97 (+0.15), ASPX: 79.99 (-6.73), ACUR: 0.69 (-0.01), XNPT: 8.38 (-0.08), SPNC: 35.89 (-0.10), CORI: 6.80 (-0.40), SAGE: 53.38 (+1.82), EBIO: 9.42 (-0.12), HAE: 44.29 (-0.22), JAZZ: 189.01 (+1.89), ICPT: 290.98 (+2.47), NVDQ: 14.00 (-0.14)
Rexahn Pharmaceuticals Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action
GlobeNewswire - Mon Feb 09, 8:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the release of an online publication describing preclinical results for Supinoxin(TM) (RX-5902) in the peer reviewed medical journal, Journal of Cellular Biochemistry, in an article titled, "A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl] piperazine (RX-5902), Interferes with β-Catenin Function through Y593 phospho-p68 RNA Helicase." The article was coauthored by Dr. Zhi-Ren Liu of the Department of Biology, at Georgia State University, and Rexahn scientists.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer
GlobeNewswire - Wed Feb 04, 8:10AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Ely Benaim, M.D. as Chief Medical Officer. In this role, Dr. Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the Company.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present a company update at the 17 Annual BIO CEO & Investor Conference being held in New York City, NY. The presentation will be on Tuesday, February 10, 2015 at 9:00am EST. An audio webcast and presentation for this conference will be available on the Company's website at www.rexahn.com in the Investor Relations section under 'Events and Presentations'.
RNN: 0.75 (+0.05)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 124.76 (-1.64), RNN: 0.75 (+0.05), NBIX: 43.60 (-0.65), ACHN: 11.06 (-0.36), ARRY: 8.00 (-0.09)
Rexahn Pharmaceuticals Down 5.3%, Shares Slide into the Red (RNN)
Comtex SmarTrend(R) - Thu Jan 15, 12:39PM CST
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.3% to $0.77 on 1.5x average daily volume. Rexahn Pharmaceuticals has traded 1.8 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.6%) and underperformed the S&P 500 (-5.3% to the S&P's -0.7%) during today's trading.
RNN: 0.75 (+0.05)
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
Sharon di Stefano - Seeking Alpha - Tue Jan 13, 11:43AM CST
When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and investors take notice. Few other accolades are held in such high esteem. In December, Rexahn Pharmaceuticals (NYSEMKT: RNN ) presented data in...
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:51AM CST
Rexahn Pharmaceuticals (RNN) was a big mover last session with its shares rising almost 13% on the day.
RNN: 0.75 (+0.05), AMAG: 58.20 (-0.04)
Can The Uptrend Continue for Rexahn Pharmaceuticals (RNN)?
Hot Stock: Rexahn Pharmaceuticals, Shares Gain 6.5% (RNN)
Comtex SmarTrend(R) - Fri Mar 20, 10:17AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 6.5% to $0.75 on 1.4x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 800,000 shares, vs. average volume of 567,000 shares per day. The stock has outperformed the Dow (6.5% to the Dow's 1.0%) and outperformed the S&P 500 (6.5% to the S&P's 0.8%) during today's trading.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference in Tokyo, Japan
GlobeNewswire - Wed Mar 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director of Business Development, will present at the 12 Annual BIO Asia International Conference in Tokyo, Japan on Wednesday, March 25, 2015 at 11:15 AM. (Japan Time). The conference is being held on March 24 to 25, 2015 at the Grand Hyatt, Tokyo, Japan.
RNN: 0.75 (+0.05)
Rexahn Pharma FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 8:33AM CDT
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals reports FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 8:12AM CDT
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update
GlobeNewswire - Tue Mar 17, 8:00AM CDT
-- Supinoxin(TM) and RX-3117 Phase I clinical trials expected to be completed in the first half of 2015
RNN: 0.75 (+0.05)
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 11.76 (-0.32), RNN: 0.75 (+0.05), PTBI: 2.91 (-0.40), DARA: 0.82 (unch), BIND: 5.87 (-0.01)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.75 (+0.05), NBIX: 43.60 (-0.65), ITEK: 5.75 (-0.19), ARIA: 8.69 (-0.28), ARRY: 8.00 (-0.09)
Rexahn Pharmaceuticals to Present at the ROTH Capital Partners 27th Annual Growth Stock Conference
GlobeNewswire - Mon Mar 02, 8:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer will present at the ROTH Capital Partners 27 Annual Growth Stock Conference on Monday, March 9, 2015 at 1:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals to Present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
GlobeNewswire - Wed Feb 18, 8:09AM CST
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director of Business Development, will present at the 3 Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Monday, February 23, 2015 at 9:15 a.m. Eastern Standard Time. The conference takes place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
RNN: 0.75 (+0.05)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 4.15 (+0.12), INSM: 21.80 (-0.20), RNN: 0.75 (+0.05), ZSPH: 49.38 (-2.11), RDHL: 13.97 (+0.15), ASPX: 79.99 (-6.73), ACUR: 0.69 (-0.01), XNPT: 8.38 (-0.08), SPNC: 35.89 (-0.10), CORI: 6.80 (-0.40), SAGE: 53.38 (+1.82), EBIO: 9.42 (-0.12), HAE: 44.29 (-0.22), JAZZ: 189.01 (+1.89), ICPT: 290.98 (+2.47), NVDQ: 14.00 (-0.14)
Rexahn Pharmaceuticals Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action
GlobeNewswire - Mon Feb 09, 8:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the release of an online publication describing preclinical results for Supinoxin(TM) (RX-5902) in the peer reviewed medical journal, Journal of Cellular Biochemistry, in an article titled, "A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl] piperazine (RX-5902), Interferes with β-Catenin Function through Y593 phospho-p68 RNA Helicase." The article was coauthored by Dr. Zhi-Ren Liu of the Department of Biology, at Georgia State University, and Rexahn scientists.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer
GlobeNewswire - Wed Feb 04, 8:10AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Ely Benaim, M.D. as Chief Medical Officer. In this role, Dr. Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the Company.
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present a company update at the 17 Annual BIO CEO & Investor Conference being held in New York City, NY. The presentation will be on Tuesday, February 10, 2015 at 9:00am EST. An audio webcast and presentation for this conference will be available on the Company's website at www.rexahn.com in the Investor Relations section under 'Events and Presentations'.
RNN: 0.75 (+0.05)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 124.76 (-1.64), RNN: 0.75 (+0.05), NBIX: 43.60 (-0.65), ACHN: 11.06 (-0.36), ARRY: 8.00 (-0.09)
Rexahn Pharmaceuticals Down 5.3%, Shares Slide into the Red (RNN)
Comtex SmarTrend(R) - Thu Jan 15, 12:39PM CST
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.3% to $0.77 on 1.5x average daily volume. Rexahn Pharmaceuticals has traded 1.8 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.6%) and underperformed the S&P 500 (-5.3% to the S&P's -0.7%) during today's trading.
RNN: 0.75 (+0.05)
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
Sharon di Stefano - Seeking Alpha - Tue Jan 13, 11:43AM CST
When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and investors take notice. Few other accolades are held in such high esteem. In December, Rexahn Pharmaceuticals (NYSEMKT: RNN ) presented data in...
RNN: 0.75 (+0.05)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:51AM CST
Rexahn Pharmaceuticals (RNN) was a big mover last session with its shares rising almost 13% on the day.
RNN: 0.75 (+0.05), AMAG: 58.20 (-0.04)
Can The Uptrend Continue for Rexahn Pharmaceuticals (RNN)?
